Alzheimer's disease is soon expected to overwhelm the national healthcare system, affecting a projected 16 million Americans and costing Medicare and Medicaid $1.1 trillion by 2050. In spite of the scientific community's relentless march forward, the reality is that we are without even one approved therapy to prevent, slow, or cure Alzheimer's. Not one. Responding to the disease's rising prevalence and skyrocketing costs, leaders at the forefront of medicine and philanthropy will imagine new approaches to therapy development that engage all sectors in battle. It is time to rewrite the playbook.

Moderator
LaTese Briggs
Senior Director, Strategy and Programs, Center for Strategic Philanthropy, Milken Institute

Speakers
Michela Gallagher
Krieger-Eisenhower Professor of Psychology and Neuroscience, Johns Hopkins University; Founder, AgeneBio, Inc.

Todd Rainwater
Chair of the Board of Trustees, Rainwater Charitable Foundation

Lauren Miller
Rogen Co-Founder, Hilarity for Charity

Garen Staglin
Founder and Chairman, One Mind